Play Live Radio
Next Up:
0:00
0:00
0:00 0:00
Available On Air Stations

WXXI's Second Opinion Show And Host Dr. Peter Salgo Nominated For An Emmy

WXXI’s national healthcare series Second Opinion and its host Dr. Peter Salgo have been nominated for a Daytime Emmy Award in the Outstanding Informative Talk Show Host category.

Dr. Salgo has been host of public television’s only regularly scheduled health series since 2003. Second Opinion is produced by WXXI, the University of Rochester Medical Center (URMC), and West 175 Productions.

“I couldn’t be prouder of our Second Opinion team and our host Dr. Peter Salgo for receiving a nomination for one of the most prestigious awards in the entire television industry,” said Norm Silverstein, President of WXXI. “We hope the entire Rochester community shares in our pride for this recognition, especially our local partners at the University of Rochester Medical Center.”

Other nominees in the category include: Dr. Mehmet Oz of The Dr. Oz Show, Larry King of Larry King Now, Steve Harvey of Steve Harvey, and The Chew co-hosts Mario Batali, Carla Hall, Clinton Kelly, Daphne Oz, and Michael Symon.

“Peter has been an integral part of Second Opinion from the very first episode,” said Elissa Orlando, Senior Vice President of TV and News, and Executive Producer of Second Opinion. “As a practicing physician, Peter is actually more than a host. He is a caring and conscientious doctor, who uses media to help people take charge of their health. We could not be more proud of Peter, or of the producers and doctors who work on Second Opinion.”

Dr. Salgo is a practicing physician at Columbia Presbyterian Hospital in New York City. This Daytime Emmy nomination comes on the heels of WXXI’s four New York Emmys Awards that the station received on March 19th.

The ceremony for The 43rd Annual Daytime Emmy Awards will be held in Los Angeles on May 1st.

Randy Gorbman is WXXI's director of news and public affairs. Randy manages the day-to-day operations of WXXI News on radio, television, and online.